Phase II NSCLC Trial To Use Median's Imaging Services

Jan 09, 2014
By Applied Clinical Trials Editors

MEDIAN Technologies, a medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced that it has signed a contract with a San Francisco-area based biotech company to provide imaging services to support a phase II clinical trial for advanced non-small cell lung cancer.

The study is anticipating imaging data from 90 clinical sites, based in 12 European countries, in the US, and in Canada. Anticipated total enrollment is 440 patients with a "first patient in" forecasted May 2014. Median will supply a set of services including clinical site qualification and training, as well as image and data collection, quality control, and storage.

Read the full release here.

lorem ipsum